Skip to content

To study the effect of Tab HFO-O2 in fatty individuals.

Clinical study to evaluate the safety and efficacy of Herbal formulation for Obesity [HFO-O2] in overweight individuals

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/07/007067
Enrollment
12
Registered
2016-07-11
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Tab HFO-O2: A combination of Triphala(150mg), Trimad(60mg), Guggul(50mg), Vrikshamla(250mg) Intervention2: Tab. HFO-O2: It contains Triphala (150 mg), Trimad (60 mg), Guggul (50mg) and

Sponsors

Baidyanath Bhavan Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Overweight individuals (Body Mass Index between 25-30) with controlled co-morbid dyslipidemia and/or hypertension and/or type 1 or type 2 diabetes 2.Stable body weight (less than 5 kg self-reported change during the previous 3 months) 3.Age between 18 years and 60 years 4.Individuals found compliant based on the Million Behavioural Medicine Diagnostic (MBMD) 5.Willing to give Informed consent before any trial-related activity takes place

Exclusion criteria

Exclusion criteria: 1.Known case of endocrinological disorders such as hyper/hypo thyroidism, Poly Cystic Ovarian Syndrome (PCOS) 2.History of use one month before screening /currently using Allopathic or Ayurvedic medicines that may cause significant weight gain 3.History of use one month before screening /currently using dietary supplements, over-the-counter medications or below mentioned Allopathic /Ayurvedic medicines for weight loss 4.Current participation (past one month) in an organized weight reduction program â?? 5.Participants with a history of major depressive or other severe psychiatric disorders or an eating disorder [judged by frequency and quantity of food] 6.Surgery scheduled for the trial duration period, except for minor surgical procedures, at the discretion of the investigator 7.Pregnant or lactating females

Design outcomes

Primary

MeasureTime frame
The outcome of the study will be measured in terms of anthropometric measurements (Weight, Body Mass Index, Waist Hip Ratio, Circumferences, Skinfold thicknesses)and Clinical signs and symptoms.Timepoint: After every 15 days

Secondary

MeasureTime frame
The secondary outcome of the study will be measured on the basis of biochemical profiling of obesity markers.Timepoint: Day 0,Day 30,Day 60,Day 90, Day 120

Countries

India

Contacts

Public ContactDr Supriya Bhalerao

Interactive Research School for Health Affairs

supriya.bhalerao@gmail.com020-24373954

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 20, 2026